A mechanistic classification of clinical phenotypes in neuroblastoma
- PMID: 30523111
- PMCID: PMC7875194
- DOI: 10.1126/science.aat6768
A mechanistic classification of clinical phenotypes in neuroblastoma
Abstract
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. Its clinical course ranges from spontaneous tumor regression to fatal progression. To investigate the molecular features of the divergent tumor subtypes, we performed genome sequencing on 416 pretreatment neuroblastomas and assessed telomere maintenance mechanisms in 208 of these tumors. We found that patients whose tumors lacked telomere maintenance mechanisms had an excellent prognosis, whereas the prognosis of patients whose tumors harbored telomere maintenance mechanisms was substantially worse. Survival rates were lowest for neuroblastoma patients whose tumors harbored telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations. Spontaneous tumor regression occurred both in the presence and absence of these mutations in patients with telomere maintenance-negative tumors. On the basis of these data, we propose a mechanistic classification of neuroblastoma that may benefit the clinical management of patients.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Conflict of interest statement
Figures
Similar articles
-
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.Cancer Res. 2020 Jun 15;80(12):2663-2675. doi: 10.1158/0008-5472.CAN-19-3068. Epub 2020 Apr 14. Cancer Res. 2020. PMID: 32291317 Free PMC article.
-
Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.Sci Rep. 2020 Dec 31;10(1):22432. doi: 10.1038/s41598-020-78370-7. Sci Rep. 2020. PMID: 33384420 Free PMC article.
-
Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond.Int J Cancer. 2022 Mar 15;150(6):903-915. doi: 10.1002/ijc.33839. Epub 2021 Oct 26. Int J Cancer. 2022. PMID: 34636058 Review.
-
Ras and Seppuku in neuroblastoma.J Natl Cancer Inst. 2002 Mar 6;94(5):319-21. doi: 10.1093/jnci/94.5.319. J Natl Cancer Inst. 2002. PMID: 11880464 No abstract available.
-
Genetic stratification of neuroblastoma for treatment tailoring.Future Oncol. 2011 Sep;7(9):1087-99. doi: 10.2217/fon.11.87. Future Oncol. 2011. PMID: 21919696 Review.
Cited by
-
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.J Pers Med. 2024 Sep 8;14(9):950. doi: 10.3390/jpm14090950. J Pers Med. 2024. PMID: 39338204 Free PMC article.
-
Pharmacologically Targeting Ferroptosis and Cuproptosis in Neuroblastoma.Mol Neurobiol. 2024 Sep 27. doi: 10.1007/s12035-024-04501-0. Online ahead of print. Mol Neurobiol. 2024. PMID: 39331355 Review.
-
Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement.J Transl Med. 2024 Aug 31;22(1):808. doi: 10.1186/s12967-024-05634-5. J Transl Med. 2024. PMID: 39217334 Free PMC article.
-
Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.JCI Insight. 2024 Jul 22;9(14):e169647. doi: 10.1172/jci.insight.169647. JCI Insight. 2024. PMID: 39133652 Free PMC article.
-
Antitumor Activity of a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting LGR5 in Preclinical Models of Neuroblastoma.Pharmaceutics. 2024 Jul 15;16(7):943. doi: 10.3390/pharmaceutics16070943. Pharmaceutics. 2024. PMID: 39065640 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous